CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


TelemedicineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (11)


Name (Synonyms) Correlation
drug453 COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support Wiki 0.58
drug2252 Sham iTBS to the dlPFC Wiki 0.58
drug2033 Real cTBS to the vmPFC Wiki 0.58
drug2034 Real iTBS to the dlPFC Wiki 0.58
drug2251 Sham cTBS to the vmPFC Wiki 0.58
drug1381 Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.41
drug1058 High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.41
drug1850 Placebo on a 0- and 28-day schedule Wiki 0.41
drug1458 Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki 0.41
drug568 Chloroquine phosphate Wiki 0.33
drug2314 Standard care Wiki 0.22

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D014029 Tobacco Use Disorder NIH 0.41
D016739 Behavior, Addictive NIH 0.29
D008180 Lupus Erythematosus, Systemic NIH 0.24
D003141 Communicable Diseases NIH 0.05
D007239 Infection NIH 0.03

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0030858 Addictive behavior HPO 0.29
HP:0002725 Systemic lupus erythematosus HPO 0.24

There are 3 clinical trials

Clinical Trials


1 Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications

The aim of the study is to evaluate whether the therapy with chloroquine phosphate (CQ, in combination with telemedical approach) in addition to standard care is effective and safe in reducing composite endpoint of COVID-19-related hospitalization or all cause death, in ambulatory patients with SARS-SoV-2 infection at particular risk of serious complications due to advanced age and/or comorbid conditions (in comparison with subjects not treated with CQ but receiving standard care and supervised telemedically).

NCT04331600 COVID-19 Drug: Chloroquine phosphate Other: Telemedicine

Primary Outcomes

Description: Composite endpoint of COVID-19-related hospitalization or all-cause death

Measure: COVID-19-related hospitalization or all-cause death

Time: 15 days

Secondary Outcomes

Description: Decrease in self-reported symptoms of novel coronavirus infection. Non-dichotomous symptoms (e.g. syncope is dichotomous - yes or no) such as dyspnoea will be self-evaluated by patients using the 0-3 scale with the severity increasing with the punctation (0-no symptoms, 1-mild symptoms, 2-moderate symptoms, 3-severe symptoms).

Measure: Decrease in COVID-19 symptoms

Time: 15 days and 42 days

Description: Based on X-ray, microbiology and laboratory results

Measure: Development of pneumonia

Time: 42 days

Description: Acute respiratory distress syndrome, bacterial infection, shock, sepsis, etc

Measure: Development of coronavirus infection-related complications

Time: 42 days

2 Assessment of COVID-19 IgM/IgG Self-testing Using Virtual Point-of-care

The goal of the research is to assess candidate COVID-19 rapid diagnostic tests (e.g. immunodiagnostic tests, like Coris Bioconcept Ag Respi-strip COVID-19 test, and LAMP-based molecular tests) in order to judge their clinical accuracy compared to Centers for Disease Control (CDC)-recommended molecular genetic testing and clinical diagnosis. Second, it is our goal to determine if self-testing assisted by COVIDscanDX mobile device camera acquisition software platform and telemedicine clinical/technical support (virtual point-of-care) improves the ease of use and immediate interpretation of the tests, thus making self-testing comparable in accuracy and safety to testing in a clinical setting. The overall purpose of the study is to dramatically increase the capacity of COVID-19 testing by establishing the safety, ease-of-use and validity of self-testing assisted by mobile device imaging and telemedicine remote support.

NCT04348864 Communicable Disease COVID-19 Sars-CoV2 Infectious Disease Coronavirus Virus Diagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support Other: Telemedicine
MeSH:Communicable Diseases Infection

Primary Outcomes

Description: Accuracy refers to the amount of agreement between the results of the antibody-based rapid test and the results of a PCR-based reference test

Measure: Clinical accuracy of the antibody and antigen rapid tests compared to LAMP/PCR-based test result

Time: 1 year

Description: Accuracy refers to the amount of agreement between the results of the rapid tests and a clinical diagnosis of COVID-19

Measure: Clinical accuracy of the antibody and antigen rapid tests based on Clinical diagnosis

Time: 1 year

Description: Clinical accuracy of the subject's visual interpretation of the test result vs image analysis from clinician

Measure: Self-test interpretation of result vs expert clinical image interpretation of result

Time: 1 year

Secondary Outcomes

Description: Subjects will complete a survey to rate the testing procedure for ease of use and convenience. The survey will ask subjects to rate the ease of use on a scale from 1 (easiest procedure to complete and understand) to 10 (most complicated and confusing procedure)

Measure: Ease of self-testing procedure

Time: 1 year

3 Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus ("TeleSLE") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial

Background Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs. The investigators hypothesize that telemedicine (TM) can be an effective mode of health-care delivery minimizing the risk of SARS-CoV-2 exposure, while maintaining disease control in these patients. Objectives The primary aim of this study is to evaluate the effectiveness to achieve remission or lupus low disease activity state (LLDAS) using TM delivered care compared to conventional in-person outpatient follow-up in SLE. The secondary objectives are to compare the patient reported outcomes and cost between the two modes of health care delivery. Study design This is a 12-months single centered pragmatic randomized controlled study. A total of 150 enrolled patients with SLE being followed at the Prince of Wales Hospital rheumatology clinics will be randomized to either TM (TM group) or standard care (SC group) in a 1:1 ratio. Patients in the TM group will receive scheduled follow-ups via videoconferencing using a custom-made mobile app. SC group patients will continue conventional standard in-person outpatient care. The disease and patient reported outcomes as well as the health care related costs will be compared. Expected outcomes Data from this study will support the notion that TM based care is as effective as conventional in-person care in achieving disease remission or LLDAS, as well as addressing psychosocial implications to ensure the best possible care for our patients in a cost-effective manner during this pandemic.

NCT04368299 SLE Other: Telemedicine Other: Standard care
MeSH:Lupus Erythematosus, Systemic
HPO:Systemic lupus erythematosus

Primary Outcomes

Measure: The percentage of patients in remission or LLDAS at one year.

Time: 1 year

Secondary Outcomes

Measure: Direct and indirect costs after one year.

Time: 1 year

Description: LupusQoL evaluates 8 domains including physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Questionnaire has a 5-point Likert response format (0=all the time, 1=most of the time, 2=a good bit of the time, 3=occasionally, and 4=never). Higher score means better quality of life.

Measure: The change of Lupus Quality of Life (LupusQoL) at one year.

Time: 1 year

Description: They are in a 5-point Likert response format (0=strongly disagree, 1=disagree, 2=neutral, 3=agree, and 4=strongly agree). Higher score means more confident and satisfied.

Measure: Patient confidence and satisfaction score at one year.

Time: 1 year

Measure: Rates of adverse reaction and severe adverse reaction, including contracting COVID-19 infection, after one year.

Time: 1 year

Measure: Numbers of clinic visits, hospitalization, overall in-person hospital visits in one year.

Time: 1 year

Description: HAQ-DI covers various common daily activities to assess disability.It consists of 8 questions. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). Higher score means higher disability.

Measure: The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year.

Time: 1 year

Description: HADS was developed to assess anxiety and depression in medical patients. Each domain has 7 items. Each item are answered by the patient on a four point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. Higher score means more likely the patient has anxiety or depression.

Measure: The change of (Hospital Anxiety and Depression Scale) HADS at one year.

Time: 1 year


Related HPO nodes (Using clinical trials)